Mostrar el registro sencillo del ítem

dc.contributor.authorDomínguez‐Carral, Jana
dc.contributor.authorLudlam, William Grant
dc.contributor.authorJunyent Segarra, Mar
dc.contributor.authorFornaguera Marti, Montserrat
dc.contributor.authorBalsells, Sol
dc.contributor.authorMuchart, Jordi
dc.contributor.authorČokolić Petrović, Dunja
dc.contributor.authorEspinoza, Iván
dc.contributor.authorOrtigoza‐Escobar, Juan Dario
dc.contributor.authorMartemyanov, Kirill A.
dc.contributor.authorCancho-Candela, Ramon
dc.date.accessioned2024-01-17T11:09:39Z
dc.date.available2024-01-17T11:09:39Z
dc.date.issued2023
dc.identifier.citationAnnals of Neurology 2023 Nov;94(5):987-1004es
dc.identifier.issn0364-5134es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/64650
dc.description.abstractObjective: GNAO1-related disorders (OMIM #615473 and #617493), caused by variants in the GNAO1 gene, are char acterized by developmental delay or intellectual disability, hypotonia, movement disorders, and epilepsy. Neither a genotype–phenotype correlation nor a clear severity score have been established for this disorder. The objective of this prospective and retrospective observational study was to develop a severity score for GNAO1-related disorders, and to delineate the correlation between the underlying molecular mechanisms and clinical severity. Methods: A total of 16 individuals with GNAO1-related disorders harboring 12 distinct missense variants, including four novel variants (p.K46R, p.T48I, p.R209P, and p.L235P), were examined with repeated clinical assessments, video electroencephalogram monitoring, and brain magnetic resonance imaging. The molecular pathology of each variant was delineated using a molecular deconvoluting platform. Results: The patients displayed a wide variability in the severity of their symptoms. This heterogeneity was well repre sented in the GNAO1-related disorders severity score, with a broad range of results. Patients with the same variant had comparable severity scores, indicating that differences in disease profiles are not due to interpatient variability, but rather, to unique disease mechanisms. Moreover, we found a significant correlation between clinical severity scores and molecular mechanisms. Interpretation: The clinical score proposed here provides further insight into the correlation between pathophysiology and phenotypic severity in GNAO1-related disorders. We found that each variant has a unique profile of clinical pheno types and pathological molecular mechanisms. These findings will contribute to better understanding GNAO1-related disorders. Additionally, the severity score will facilitate standardization of patients categorization and assessment of response to therapies in development.es
dc.format.mimetypeapplication/pdfes
dc.language.isospaes
dc.publisherWileyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleSeverity of GNAO1‐Related Disorder Correlates with Changes in G‐Protein Functiones
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1002/ana.26758es
dc.identifier.publicationfirstpage987es
dc.identifier.publicationissue5es
dc.identifier.publicationlastpage1004es
dc.identifier.publicationtitleAnnals of Neurologyes
dc.identifier.publicationvolume94es
dc.peerreviewedSIes
dc.identifier.essn1531-8249es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem